Expand BMRN Menu
BMRN MENU

BMRN Latest Press Releases

-- December 26, 2025 --

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD Business Wire 3:28 PM

-- December 19, 2025 --

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook PRNewswire 7:45 AM

-- November 11, 2025 --

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England PRNewswire 9:00 AM

-- October 29, 2025 --

FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria PRNewswire 9:00 AM

-- October 27, 2025 --

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update PRNewswire 4:03 PM

-- October 22, 2025 --

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET PRNewswire 4:05 PM

-- September 8, 2025 --

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting PRNewswire 9:00 AM

-- September 6, 2025 --

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism PRNewswire 11:05 AM

-- August 27, 2025 --

BioMarin to Participate in Upcoming Investor Conferences PRNewswire 9:00 AM
Market Data Delayed 15 Minutes